Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension

This publication has 31 references indexed in Scilit:

• A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy
  Current Medical Research and Opinion, 2005
• PEY3 REFILL COSTS AND BUDGET IMPACT OF GLAUCOMA LIPID THERAPY: A RETROSPECTIVE DATABASE ANALYSIS
  Value in Health, 2005
• Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom
  Journal of Medical Economics, 2005
• A Persistency and Economic Analysis of Latanoprost, Bimatoprost, or Beta-Blockers in Patients with Open-Angle Glaucoma or Ocular Hypertension
  Journal of Ocular Pharmacology and Therapeutics, 2004
• PAE11 ECONOMIC EVALUATION OF LATANOPROST AS FIRST LINE GLAUCOMA THERAPY IN 6 EUROPEAN COUNTRIES
  Value in Health, 2003
• PAE10 COMPARISON OF THE CLINICAL EFFICACY AND COST-EFFECTIVENESS OF LUMIGAN AND XALATAN IN THE TREATMENT OF GLAUCOMA
  Value in Health, 2003
• CS1 A MARKOV MODELLED PHARMACOECONOMIC ANALYSIS OF BIMATOPROST 0.03% (LUMIGAN®) IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION AS AN ALTERNATIVE TO FILTRATION SURGERY IN ITALY
  Value in Health, 2003
• PES5: MODEL-BASED COMPARATIVE PHARMACOECONOMIC ANALYSES OF BIMATOPROST 0.03% IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION IN ADULT PATIENTS IN AUSTRIA AND FINLAND
  Value in Health, 2003
• PES4: COST-EFFECTIVENESS OF BIMATOPROST 0.03% VERSUS A COMBINATION PRODUCT OF TIMOLOL 0.5% AND DORZOLAMIDE 2.0% FOR GLAUCOMA
  Value in Health, 2003
• PES2: COST-EFFECTIVENESS OF BIMATOPROST VERSUS LATANOPROST PLUSADJUNCTIVE PRODUCTS FOR GLAUCOMA TREATMENT
  Value in Health, 2003